Progress in Cardiology Noninvasive tests of vascular function and structure: Why and how to perform them Robert Fathi, MBBS, and Thomas H. Marwick, MBBS, PhD, FACC Brisbane, Australia Background Early atherosclerosis involves the endothelium of many arteries. Information about peripheral arterial anatomy and function derived from vascular imaging studies such as brachial artery reactivity (BAR) and carotid intima media thickness (IMT) may be pertinent to the coronary circulation. The prevention and early treatment of atherosclerosis is gaining more attention, and these tests might be used as indications or perhaps guides to the effectiveness of therapy, but their application in clinical practice has been limited. This review seeks to define the anatomy and pathophysiology underlying these investigations, their methodology, the significance of their findings, and the issues that must be resolved before their application. Methods The literature on BAR and IMT is extensively reviewed, especially in relation to clinical use. Results Abnormal flow-mediated dilation is present in atherosclerotic vessels, is associated with cardiovascular risk factors, and may be a marker of preclinical disease. Treatment of known atherosclerotic risk factors has been shown to improve flow-mediated dilation, and some data suggest that vascular responsiveness is related to outcome. Carotid IMT is associated with cardiovascular risk factors, and increased levels can predict myocardial infarction and stroke. Aggressive risk factor management can decrease IMT. Conclusions BAR and IMT are functional and structural markers of the atherosclerotic process. The clinical use of BAR has been limited by varying reproducibility and the influence by exogenous factors, but IMT exhibits less variability. A desirable next step in the development of BAR and IMT as useful clinical tools would be to show an association of improvement in response to treatment with improvement in prognosis. (Am Heart J 2001;141:694-703.) Significance of vascular structure and function to cardiologists Coronary angiography and standard functional tests have been the cornerstone of the diagnosis and management of coronary artery disease for decades. However, as the emphasis of cardiovascular care moves progressively toward prevention and regression of earlier disease, these tools may become less effective in diagnosing early subclinical disease, in which the greatest potential gain exists. Functional tests identify disease in the setting of significant coronary stenoses, which implies the presence of advanced disease. Coronary angiography may be used to identify earlier lesions1 but is restricted to analyzing the lumen and does not directly assess the vessel wall. Furthermore, it is ill suited to sequential follow-up, and, being an invasive study, carries the potential of significant adverse effects. From the University of Queensland. Supported in part by a grant from the National Health and Medical Research Foundation, Australia. Submitted October 13, 2000; accepted February 9, 2001. Reprint requests: Prof T. Marwick, University of Queensland, Department of Medicine, Princess Alexandra Hospital, Ipswich Road, Brisbane, Qld 4012, Australia. E-mail: [email protected] Copyright © 2001 by Mosby, Inc. 0002-8703/2001/$35.00 + 0 4/1/114972 doi:10.1067/mhj.2001.114972 Given that early atherosclerosis involves the endothelium of many arteries, several noninvasive tests may provide information about peripheral arterial anatomy and function that may be pertinent to the coronary arteries. The application of these tests in clinical practice has been limited by a number of factors including limited data (especially regarding flow-mediated vasodilation), technical considerations, and in part by the field of vascular imaging being outside the standard repertoire of cardiologists. However, as the prevention and early treatment of disease gains more attention, these tools may become important as indications or perhaps guides to the effectiveness of therapy. This review seeks to define the anatomy and pathophysiology underlying these investigations, their methodology, the significance of their findings, and the factors that must be defined before their clinical application. Vascular function and early atherosclerosis Endothelial dysfunction in relation to imaging protocols Since the landmark 4S study,2 many investigations have shown cholesterol lowering to be associated with a marked decrease in cardiac events and mortality rates, American Heart Journal Volume 141, Number 5 yet the actual improvement in coronary vasculature as assessed by angiography has been small.3 Other mechanisms to explain this discrepancy have been suggested, including a direct beneficial effect on endothelial function. Moreover, vascular dysfunction associated with vascular injury has been postulated as the precursor of atherosclerosis.4 Impaired endothelial function has been exhibited in asymptomatic children and young adults who have risk factors for atherosclerosis including hypercholesterolemia and cigarette smoking.5 The implications of this are significant. Tests of endothelial function may be used to diagnose early disease and track the response to various treatments that cause disease regression. Endothelial dysfunction may indeed predict outcome; therefore its reversal may have important clinical implications. The primary agent used to assess coronary endothelial function in the coronary circulation is selective intracoronary infusion of acetylcholine (10–8 to 10–6 mol/L).6 In the normal coronary vasculature, acetylcholine releases nitric oxide (NO) and causes vasodilation, but in the presence of atherosclerosis, associated with reduced NO release,7 acetylcholine causes a paradoxic vasoconstriction secondary to a net muscarinic smooth muscle cell activation. This is in contrast to the normal vasodilator response to glyceryl trinitrate, which provides an exogenous NO source. Peripheral tests of vascular function Methodology. Direct measurements of coronary flow responses are invasive and not readily repeatable. In patients with chest pain, impaired brachial artery flowmediated vasodilation (FMD) has been reported in patients with an abnormal coronary endothelial function as compared with those with normal coronary endothelial function (FMD, 4.8% ± 5.5% vs 9.7% ± 8.1%, P < .02).8 Peripheral tests have therefore been applied as a surrogate for coronary reactivity. Vasodilator responses in the peripheral vessels have traditionally been evaluated with plethysmography. In this test, a strain gauge is placed around the forearm, cuffs are then placed at the wrist and the upper arm, and the wrist cuff is inflated to 200 mm Hg to prevent blood circulation in the hand. After the upper arm cuff is inflated to 40 mm Hg, venous occlusion causes forearm engorgement, which is then recorded on the plethysmograph to derive measurement of resting blood flow. After this, the cuff is inflated to suprasystolic pressures for between 4 and 10 minutes and then deflated, thereby measuring hyperemic blood flow. However, plethysmography remains technically difficult, and the recognition of a good waveform is somewhat subjective; it is not likely to develop into a standard clinical tool. The most widely used alternative to invasive, direct testing of the coronary vasculature is a noninvasive Fathi and Marwick 695 method of testing brachial and femoral artery endothelial function, based on the technique described by Celermajer et al.5 Attention to detail is important: Patients are studied in the fasting state; caffeine and cigarette smoking are prohibited on the morning of the study because of their documented acute influences on vascular physiology.9,10 Similarly, vasoactive medications including angiotensin-converting enzymes, calcium entry blockers, and β-blockers are withheld for 24 hours before the study, assuming the patient is stable from a cardiovascular viewpoint. After the patient had been lying at rest for 5 minutes, the brachial artery is located above the elbow. To standardize the technique and reduce variability, we use the right brachial artery whenever possible. Longitudinal images of 6 to 8 cm are optimized, and a resting scan is taken, including a 10-second measurement of Doppler flow. Complete occlusion of the artery is needed for the duration of the scan. The cuff is placed on the forearm11 and inflated to 300 mm Hg for a duration of 4.5 minutes. The cuff is deflated, and after 15 seconds of hyperemic Doppler flow, the second or hyperemic scan is obtained at approximately 1 minute after deflation, when peak brachial artery dilation occurs.12 The patient is allowed to rest for 15 minutes, and a second resting scan is then acquired. Three minutes after administration of 400 µg of sublingual nitroglycerin, a fourth scan is obtained (Figure 1). Celermajer et al5 found an FMD of approximately 10% in a control group between 8 and 57 years of age, with no classic risk factors for coronary artery disease. Correlates of endothelial dysfunction. Although present in established cardiovascular disease, impaired FMD is also a marker of the preclinical phase of overt vascular disease.13 In a study of 500 clinically well, nonhypertensive subjects, 5 to 73 years of age, lower levels of FMD were associated on univariate analysis with hypercholesterolemia, cigarette smoking, hypertension, male sex, larger vessel size, and family history of premature vascular disease. Several cardiovascular risk factors have been associated with abnormalities of endothelial function. In a comparison of femoral artery FMD in 16 patients (42 ± 4 years of age) with primary hypercholesterolemia who had no overt cardiovascular disease with 16 normocholesterolemic control patients (35 ± 3 years of age), Arcaro et al14 demonstrated a statistically significant difference in the area under the curve of the time-dependent femoral artery diameter change. Gerhard et al15 studied endothelial function of 119 healthy volunteers 19 to 69 years of age with no clinical cardiovascular disease by using venous occlusion plethysmography. Brachial artery metacholine infusion was used for assessment of endothelium-dependent vasodilation and intra-arterial sodium nitroprusside infusion for endothelium-independent vasodilation. The slope of the meta- 696 Fathi and Marwick American Heart Journal May 2001 Figure 1 Brachial artery diameter measurements before and after arterial occlusion; measurement in same site is important and can be guided by external landmarks as well as other features on the ultrasound image. choline–blood flow response was indicative of endothelium-dependent vasodilation and exhibited a progressive decline with each decade increase in age. Similar results have been shown with brachial artery infusions of an NO synthase inhibitor, NG-monomethyl-L-arginine (L-NMMA).16 The response of groups with documented vascular disease is similar: In an older population with symptomatic peripheral vascular disease, impaired FMD has been reported in comparison with age-matched control patients without peripheral vascular disease.17 Other correlates of impaired FMD include the extent of coronary artery disease, the maximum percent diameter stenosis in any of the major coronary arteries, and brachial artery diameter.18 Impaired FMD in the brachial artery has been shown to correlate with the angiographic extent of coronary artery disease in 74 patients with angina pectoris when a cutoff of ≥30% diameter was used.18 It should be noted that this cutoff value should be distinguished from “significant”coronary artery disease. In a pilot study, Schroeder et al19 proposed that endothelial dysfunction as quantified by FMD could be used as a screening test for coronary artery disease. One hundred twenty-two consecutive patients with a clinical suspicion of coronary artery disease who had no previous invasive investigations underwent coronary angiography as well as a stress modality (either exercise electrocardiography or myocardial perfusion imaging). Of these patients, 101 were found to have the presence of any angiographically detectable disease of any severity. FMD of the brachial artery was better in the group with no coronary artery disease (7.0% ± 3.5%) as opposed to the group with coronary artery disease (3.8% ± 4.1%, P < .001). However, FMD could not significantly differentiate between the various grades of severity of coronary artery disease. FMD demonstrated a sensitivity of 71% and a specificity of 81% in predicting any coronary artery disease. Receiver operating characteristic analysis found the optimal cutoff point for FMD in terms of sensitivity and specificity in predicting coronary artery disease as being ≤4.5%. It should be noted that this value is different from those of previous studies5 and probably is related to different patient group selection. Response of vascular reactivity to interventions that alter endothelial dysfunction. Endothelium-medi- ated responses of the coronary arteries have been shown to improve in response to treatment of atherosclerotic risk factors. Aggressive lipid lowering with lovastatin has been shown to cause a significant improvement in the endothelium-mediated response of the coronary arteries in 23 patients 30 to 81 years of age with coronary artery disease requiring angioplasty, as assessed by serial examinations with intracoronary acetylcholine at baseline and at 6 months. After 6 months, patients receiving placebo had –18% ± 5% change in coronary artery diameter as compared with those receiving lovastatin, who had 0% ± 3% change in response to acetylcholine at a dose of 10–6 mol/L.20 Similarly, the use of probucol confers improved coronary vascular function when added to standard lipid therapy.21 Gould et al22 demonstrated improved myocardial perfusion by using a PET scanner as early as 3 months after commencement of treatment. The correlation of coronary and peripheral reactivity suggests that peripheral parameters might also be used to track treatment responses. Indeed, even a single episode of low-density lipoprotein (LDL) apheresis can improve endothelial function, as measured by forearm plethysmography and local acetylcholine infusion.23 In American Heart Journal Volume 141, Number 5 10 patients with hypercholesterolemia (serum cholesterol between 6.0 and 10.0 mmol/L), the use of simvastatin has been shown to improve forearm vasodilator response to acetylcholine within 4 weeks of commencement.24 Finally, in a group of patients with acute myocardial infarction or unstable angina pectoris and a total cholesterol level ≥5.2 mmol/L or LDL ≥3.4 mmol/L, Dupuis et al25 demonstrated a 42% relative increase (from 4.93% ± 0.81% to 7.0% ± 0.79%) in brachial FMD in the group of patients treated with 40 mg pravastatin daily as compared with those who received placebo after 6 weeks. A number of other interventions have also been shown to influence vascular function, measured by FMD and other techniques. Endothelial NO production appears to be related to the renin-angiotensin system,26 and a number of studies have examined this link at the basic and clinical levels. In the TREND study,27 angiotensin-converting enzyme inhibition with quinapril was associated with improved coronary endothelial function in a normotensive group of 129 patients with 1- or 2-vessel coronary artery disease requiring nonsurgical revascularization with no evidence of severe hyperlipidemia or overt cardiac failure. More recently, Anderson et al28 compared quinapril, enalapril, losartan, and amlodipine on brachial FMD in 80 patients (mean age, 58 ± 0.9 years) in a crossover design. These patients had ≥50% stenosis in a major epicardial vessel on angiography in the preceding 6 months. From the baseline FMD of 7.3% ± 0.6%, quinapril resulted in a statistically significant increase in absolute FMD of 1.8% ± 1% (P < .02). The changes with the other medications were not significant. Other studies of angiotensin-converting enzyme inhibition have produced more variable findings, perhaps reflecting some variability in the group. O’Driscoll et al29 assessed FMD with forearm plethysmography in a group of 10 men (mean age, 60 ± 3 years) with non–insulin-dependent diabetes mellitus who were treated with 10 mg enalapril twice daily or placebo for 4 weeks. Vasodilation as assessed by forearm blood flow ratio (ratio of flow in infused to noninfused arm) in response to acetylcholine was greater in those receiving enalapril (3.60 ± 0.55 vs placebo, 2.63 ± 0.34 at infusion rate of 40 µg/min acetylcholine; P < .02). In a similar study by Cheetham et al30 of a group of 9 patients (mean age, 54 ± 2 years) with noncomplicated non–insulin-dependent diabetes mellitus, the use of losartan, an angiotensin type 1 receptor antagonist at a dose of 50 mg per day, demonstrated improved forearm blood flow compared with those receiving placebo. Not all studies have shown a positive result. In a young group of insulin-dependent diabetic patients (mean age, 30.9 years), 6 months of treatment with 20 mg enalapril once daily did not result in a significant difference in brachial artery FMD.31 Fathi and Marwick 697 Vasodilator reserve correlates with circulating levels of estradiol-17β, and postmenopausal women have impaired forearm blood flow and vasodilator capacity. The latter has been shown to improve with administration of estrogen.32 In a study of 17 postmenopausal women (mean age, 60 years) with no clinical manifestation of cardiovascular disease, the introduction of estradiol was associated with an improved brachial artery FMD (from 4.7% ± 0.06% to 11.1% ± 1.0%, P < .001) with no statistical difference when progesterone is added to estradiol therapy.33 Finally, improved endothelial function has been previously exhibited with the administration of L-arginine. Intravenous administration of L-arginine has been shown to significantly improve FMD in both hypercholesterolemic patients as well as in smokers but not in a diabetic subset.34 Finally, there is evidence that vascular responsiveness correlates with outcome. In 147 patients who were followed for a median of 7.7 years, Schächinger et al35 demonstrated significantly increased cardiovascular events (cardiovascular death, unstable angina, myocardial infarction, revascularization, and ischemic stroke) in patients with an abnormal coronary vascular response to acetylcholine or nitroglycerin and thus gave the first evidence of the prognostic significance of coronary vascular dysfunction. Suwaidi et al36 followed 157 patients with mild coronary artery disease (lesions <40% stenosis) over a period of 28 months. They demonstrated no cardiac events (cardiac death, myocardial infarction, and revascularization) in those with normal or mild coronary endothelial dysfunction with coronary artery acetylcholine infusion (percent change in coronary blood flow between 0% and 50%). However, those with severe endothelial dysfunction (percent change in coronary blood flow <0%) had a 14% cardiac event rate (P < .05 compared with those with normal and mildly decreased endothelial function). Because FMD correlates with coronary reactivity, analogous results might be anticipated, but this remains speculative. Barriers to application of brachial reactivity as a clinical tool. Although impaired FMD is often seen in patients with coronary artery disease, its specificity for significant stenoses is poor, probably because of a strong correlation with atherosclerotic risk factors and mild disease. It may perhaps have value as a screening test in that coronary disease might be unlikely in the presence of a normal test, but there is insufficient evidence to apply this currently. This test would be more likely to find application in determining the response of the endothelium to various interventions if the degree of change were greater than would be expected with the innate variability of this test. However, the main limitation in this respect is likely to be the reproducibility of the test. Sorensen et al37 calculated that in clinical trials, a mean improvement of FMD of ≥2% is necessary to detect treatment American Heart Journal May 2001 698 Fathi and Marwick Figure 2 Brachial artery reactivity measurement with automatic edge-detection software. benefit and that for any one individual, a difference of 4% to 8% was necessary to account for natural variability. However, the level of variation reported in the original studies may have been colored by the means of expressing this variability, and subsequent workers have reported greater variations. In a study of normal adults 20 to 70 years of age (mean, 46.5) studied a mean of 2.5 weeks apart, Liang et al38 reported a mean FMD of 10.8%, with a coefficient of variability of 10.8% and an r value of 0.70. The cause of this variation is multifactorial; to some extent, it may reflect variability in the sampling site and inconsistency in drawing the lumen-endothelium interface, which could be improved by automated methods of drawing the borders (Figure 2). To a large extent, it may reflect the exquisite short-term sensitivity of this parameter to various stimuli, including diet; for example, transient decreases in FMD in normal volunteers have been exhibited with fatty meals and even a diet high in olive oil.39,40 Vascular structure and atherosclerotic burden Background Early lesions consistent with atherosclerosis have been documented in young adults and even children and progress with aging.41 Ultrasonography of the peripheral vessels (as opposed to angiography) is an accurate investigation for the extent of atherosclerosis because early lesions may progress with no decrease in intraluminal diameter because of concomitant vessel wall dilation. Magnetic resonance imaging and intravascular and transesophageal ultrasound techniques have been applied to the evaluation of plaque burden. Newer techniques such as electron-beam computed tomography and spiral computed tomography have recently been applied in the investigation of atherosclerotic burden but as yet have an ill-defined role in clinical practice. However, the measurement of carotid intima-medial thickness (IMT) is highly feasible and appears to reflect the early stages of atherosclerosis.42 Because it is noninvasive and does not expose the patient to radiation, it can be used in asymptomatic patients, and serial measurements can be readily obtained, although further work is needed to establish its role in clinical practice. Technical aspects of measurement of IMT Scanning of the extracranial carotid arteries is performed with the patient lying supine, the head directed away from the side of interest, and the neck extended slightly. Both the left and right common carotid arteries are imaged at the level of the carotid bifurcation in anterior, lateral, and posterior planes. The focal zone is set at or just below the far wall, which is scanned perpendicular to the transducer face. On a longitudinal B-mode image of the carotid artery, a series of echogenic “lines” and nonechogenic “spaces” is displayed42 (Figure 3). An echogenic line is produced when the beam passes through an acoustic interface, which generates a “leading” edge echo as well as a “trailing” edge, which is gain dependent. The distance between two leading edges can be reliably measured, but because the trailing edge is gain dependent, it does not always correspond anatomically to any structure, hence the unreliability and large error in near-wall measurements. In Figure 3, the leading edge American Heart Journal Volume 141, Number 5 Fathi and Marwick 699 Figure 3 Carotid IMT measurement. Trailing edge of first echogenic line (1) corresponds to adventitia interface followed by leading edge of intima (2), which defines beginning of measured lumen. From here, leading edge of next echogenic line corresponds to lumen-intima interface (3, far wall of lumen), which is then followed by leading edge of media-adventitia interface (4), both of which define IMT of far wall.43 of the first echogenic line corresponds to the adventitia interface, followed by the leading edge of the intima. From here, the leading edge of the next echogenic line corresponds to the lumen-intima interface (far wall of the lumen), which is then followed by the leading edge of the media-adventitia interface, both of which define the IMT of the far wall.43 The intimal layer must be differentiated from plaque, which often exhibits calcification (bright echo) or localized protrusion into the lumen. Although various investigators have measured the common, internal, and external carotid vessels, the most reliable measurements are obtained from the distal 2 cm of the common carotid artery, proximal to its bifurcation.44 This region has advantages in being close to the skin surface and being relatively parallel to it. Clinical significance of measurements of IMT Carotid IMT may have clinical application as a marker of atherosclerosis development in the setting of various risk factors, a marker of response to therapy for atherosclerosis, a predictor of events, and a marker of advanced vascular disease in the peripheral, carotid, and coronary circulations. Hashimoto et al45 compared the IMT and brachial FMD of 34 men with atherosclerosis with 33 age-matched men without clinical atherosclerosis. There was a significantly smaller percentage of FMD in those patients with atherosclerosis than those without (2.78% vs 5.10%, P < .05). In all 67 patients, IMT was inversely related to FMD (r = –0.36, P < .01), and after accounting for covariables in a multivariate analysis, IMT remained inversely related to percent FMD (r = –0.29, P = .03). A number of large studies have demonstrated the strong relation between IMT and cardiovascular risk factors. Increased carotid IMT has been associated with diabetes, fibrinogen level, body mass index, and clinically overt atherosclerosis.46 Other studies have associated IMT with abnormal glucose metabolism, abdominal adiposity, and fasting plasma insulin levels in patients without cardiovascular disease.47,48 Lower levels of increased IMT probably reflect the early stages of vessel involvement, whereas the vessel enlarges before lumenal narrowing occurs. In a study of 1715 patients >55 years of age, inner and outer lumen diameter increased gradually up to an IMT of 1.0 to 1.1 mm, after which there was a decrease in the inner lumen diameter suggesting the presence of atherosclerotic thickening.49 Indeed, it is thought that IMT rather than localized plaque may be a good marker of the total body atherosclerotic burden.49,50 Variable annual rates of increase in IMT have been described, probably reflecting racial differences in the progression of atherosclerosis. Salonen and Salonen51 found in 100 Finnish men (between 42 and 60 years of age) over a period of 24 months a mean increase in IMT of 0.12 ± 0.20 mm. Hodis et al52 investigated the annual rate of change of IMT in 146 American men 40 to 59 years of age who had previous coronary bypass grafting. Patients on dietary management had an annual 700 Fathi and Marwick increase in IMT of 0.021 ± 0.02 mm, whereas those receiving dietary plus colestipol-niacin therapy had an annual decrease in IMT of –0.024 ± 0.03 mm. The strongest predictors of the 2-year increase in carotid IMT in 128 Finnish men included age, LDL, smoking, and platelet aggregability.43 Lipid lowering has been shown to slow the progression of IMT. In a study of 151 patients with documented coronary artery disease, treatment with pravastatin resulted in a relative reduction in IMT progression of 35% compared with the placebo group (0.0295 mm/y vs 0.0456 mm/y, P = .03).53 Reduction in the progression of peripheral atherosclerosis has been shown to correlate with parallel trends in the coronary vasculature, as addressed by quantitative coronary angiography.54 There is growing evidence that IMT may predict myocardial infarction and stroke prospectively. Increasing levels of common carotid IMT are associated with an incremental risk of stroke and myocardial infarction. In one study, 5858 patients >65 years of age with no preexisting cardiovascular disease were separated into quintiles on the basis of maximal common carotid artery IMT and followed for a mean period of 6.2 years. Over this period, 47 of 897 patients in the lowest quintile of IMT (<0.87 mm) had a stroke or myocardial infarction. In comparison, those in the highest quintile of IMT (≥1.18 mm) had 167 events. This equated to an age- and sex-adjusted relative risk of 2.85.55 Carotid IMT has been used as a marker of advanced atherosclerosis of other vessels. Sorensen et al56 performed postmortem comparison of histologic grading of atherosclerosis of the brachial, coronary, and carotid arteries, in which atherosclerotic change was classified as fatty streak, fibrous plaque, or advanced lesion in 52 consecutive patients between 21 and 79 years of age. They demonstrated significant correlations of the grade of lesion severity in the brachial and coronary (r = 0.41, P = .003), the brachial and carotid (r = 0.53, P = .0001), and the carotid and coronary arteries (r = 0.69, P = .0001). In a prospective study of 1000 patients ≥55 years of age, Bots et al57 demonstrated an inverse relation between carotid IMT and the ankle-brachial index. Linear regression analysis, corrected for age and sex, revealed that for each 0.1-mm increase in carotid IMT, there existed a decrease in the ankle-brachial index of 0.026, suggesting that carotid IMT is indicative of arterial disease in different vascular beds. Finally, in 276 patients referred for ultrasound examination of carotid arteries, Gnasso et al58 demonstrated an increased prevalence of carotid atherosclerosis (defined as plaque with IMT ≥2.0 mm or Doppler evidence of stenosis) with each increase in IMT tertile. For men, 19% in the lowest tertile had carotid atherosclerosis as opposed to 50% in the highest tertile (P < .02). A relation between carotid and coronary atheroscle- American Heart Journal May 2001 rosis has long been known,59 but the ability of IMT to act as a surrogate marker for coronary artery disease is debatable. A significant overlap exists between patients with and those without coronary artery disease (luminal stenosis ≥70%) and elevated IMT. In a study of 350 patients undergoing coronary angiography, mean carotid IMT was only weakly correlated to both severity and extent of coronary artery disease (r = 0.26, P < .0001).60 Nonetheless, a significant association between asymptomatic exercise-induced myocardial ischemia and increased carotid IMT has been reported.61 A graded increase in IMT was shown from community-based patients with no coronary artery disease (n = 397; age, 58.5 ± 15.8 years), possible coronary artery disease in which exercise electrocardiography revealed ≥1 mm of horizontal or downsloping ST-segment depression (n = 72; age, 66.1 ± years), and definite coronary artery disease (n = 38; age 77.4 ± 7.8 years). Furthermore, a subset of those with possible coronary artery disease underwent exercise thallium scintigraphy, subdividing this group into low and high risk by a negative or positive result. Common carotid artery IMT progressively increased in the patients with no coronary artery disease (0.52 ± 0.14 mm) to possible (low-risk) coronary artery disease (0.61 ± 0.12 mm) to possible (high-risk) coronary artery disease (0.74 ± 0.10 mm) to definite coronary artery disease (0.75 ± 0.16 mm). Regression analysis revealed that for each 0.1-mm increase in IMT, there is an associated 1.91times increased risk of a positive exercise stress test or clinically manifest coronary artery disease, even by controlling for the effects of age, hypertension, and lipidlowering medication. Barriers to application of IMT as a clinical tool The literature regarding IMT has been derived from groups of patients, and an evidence base regarding its application in individuals is still to be developed. Nonetheless, the test is more reliable than FMD, in the sense of being less influenced by acute changes in the patient’s milieu. Stensland-Bugge et al62 have shown that the measurement of carotid IMT is reproducible and that measurement error is more likely with increasing levels of IMT. Reliable serial IMT was demonstrated in the large ACAPS study (Asymptomatic Carotid Artery Progression Study), which involved 919 participants.63 Smaller studies have given acceptable results in terms of interobserver and intra-observer variabilities.64 The recent development of automated techniques to measure IMT may improve the reliability of this measurement in less expert readers. In a study that used a mobile field scanner, Dwyer et al65 exhibited a withinsonographer mean absolute difference between baseline and follow-up scans of the common carotid artery IMT of 0.027 mm and a coefficient of variation of 4.2%. American Heart Journal Volume 141, Number 5 The between-sonographer (both within and between visit) mean absolute difference was 0.041 mm, with a coefficient of variation of 6.1%. Requirements for clinical application The current treatment of atherosclerosis involves biochemical targets, the selection of which is based on a large evidence base of outcome studies such as the 4S study.66,67 Nonetheless, this approach neglects the continuum of risk, even at “normal” lipid levels, and the interaction with other risk factors. A means of quantifying atherosclerotic burden or the adverse effects of risk factors on vascular function may be of value in decision-making regarding the initiation of treatment in patients with borderline lipid values, in guiding the addition of other agents, and in providing information to patients regarding the efficacy of treatment. Moreover, these investigations may be used as a surrogate of outcome in research studies. The current application of these investigations has been across populations and in tightly controlled research groups. Although increased IMT has been shown to prospectively predict myocardial infarction and stroke55 and abnormal coronary endothelial function has been shown to be predictive of cardiovascular events,35,36 this has not yet been validated with regard to peripheral arterial reactivity. Furthermore, although a number of studies have been described in which the introduction of an intervention has improved either FMD or IMT, prospective studies are required that exhibit that the improved FMD or IMT is also associated with improved cardiovascular events or prognosis. Before these investigations can be applied to individual patients, more automated and reproducible measurement approaches are needed. Recent developments in border recognition may facilitate automated approaches that reduce test-retest variation and move the tests into routine clinical practice. Fathi and Marwick 701 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. References 1. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 1990; 119:1262-7. 2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9. 3. Brown BG, Zhao XQ, Sacco DE, et al. Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Annu Rev Med 1993;44:36576. 4. Ross R. Atherosclerosis: current understanding of mechanisms and future strategies in therapy. Transplant Proc 1993;25:2041-3. 5. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detec- 20. 21. 22. 23. tion of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51. Oemar BS, Tschudi MR, Godoy N, et al. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998;97:2494-8. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-41. Quinlan PT, Lane J, Moore KL, et al. The acute physiological and mood effects of tea and coffee: the role of caffeine level. Pharmacol Biochem Behav 2000;66:19-28. Motoyama T, Kawano H, Kugiyama K, et al. Endothelium-dependent vasodilation in the brachial artery is impaired in smokers: effect of vitamin C. Am J Physiol 1997;273:H1644-50. Mannion TC, Vita JA, Keaney JF Jr, et al. Non-invasive assessment of brachial artery endothelial vasomotor function: the effect of cuff position on level of discomfort and vasomotor responses. Vasc Med 1998;3:263-7. Uehata A, Lieberman EH, Gerhard MD, et al. Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med 1997;2:87-92. Celermajer DS, Sorensen KE, Bull C, et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24:1468-74. Arcaro G, Zenere BM, Travia D, et al. Non-invasive detection of early endothelial dysfunction in hypercholesterolaemic subjects. Atherosclerosis 1995;114:247-54. Gerhard M, Roddy MA, Creager SJ, et al. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996;27:849-53. Lyons D, Roy S, Patel M, et al. Impaired nitric oxide-mediated vasodilatation and total body nitric oxide production in healthy old age. Clin Sci (Colch) 1997;93:519-25. Yataco AR, Corretti MC, Gardner AW, et al. Endothelial reactivity and cardiac risk factors in older patients with peripheral arterial disease. Am J Cardiol 1999;83:754-8. Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997;129:111-8. Schroeder S, Enderle MD, Ossen R, et al. Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. Am Heart J 1999;138: 731-9. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterollowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-8. Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves American Heart Journal May 2001 702 Fathi and Marwick 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31. Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999;99:3227-33. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors: a new trend. Circulation 1996;94:240-3. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-65. Anderson TJ, Elstein E, Haber H, et al. Comparative study of ACEinhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60-6. O’Driscoll GA, Benkelfat C, Florencio PS, et al. Neural correlates of eye tracking deficits in first-degree relatives of schizophrenic patients: a positron emission tomography study. Arch Gen Psychiatry 1999;56:1127-34. Cheetham C, Collis J, O’Driscoll G, et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in noninsulin-dependent diabetes. J Am Coll Cardiol 2000;36:1461-6. Mullen MJ, Clarkson P, Donald AE, et al. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized, double-blind study. J Am Coll Cardiol 1998;31:1330-5. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994;89:2545-51. Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998;98:1158-63. Thorne S, Mullen MJ, Clarkson P, et al. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to Larginine. J Am Coll Cardiol 1998;32:110-6. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54. Sorensen KE, Celermajer DS, Spiegelhalter DJ, et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995;74:247-53. Liang YL, Teede H, Kotsopoulos D, et al. Non-invasive measurements of arterial structure and function: repeatability, interrelationships and trial sample size. Clin Sci (Colch) 1998;95:669-79. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997;79: 350-4. Vogel RA, Corretti MC, Plotnick GD. The postprandial effect of components of the Mediterranean diet on endothelial function. J Am Coll Cardiol 2000;36:1455-60. Belcaro G, Laurora G, Cesarone MR, et al. Evaluation of arteriosclerosis progression with ultrasonic biopsy and intima-media thickness measurements. Vasa 1993;22:15-21. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-406. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993;87:II-5665. Wikstrand J, Wendelhag I. Methodological considerations of ultrasound investigation of intima-media thickness and lumen diameter. J Intern Med 1994;236:555-9. Hashimoto M, Eto M, Akishita M, et al. Correlation between flowmediated vasodilatation of the brachial artery and intima-media thickness in the carotid artery in men. Arterioscler Thromb Vasc Biol 1999;19:2795-800. Poredos P, Kek A, Verhovec R. Morphological and functional changes of the arterial wall in subjects at risk of atherosclerosis and in patients with peripheral arterial occlusive disease. Vasa 1997; 26:271-6. Folsom AR, Eckfeldt JH, Weitzman S, et al. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke 1994;25:66-73. Agewall S, Fagerberg B, Attvall S, et al. Carotid artery wall intimamedia thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke 1995;26:956-60. Bots ML, Hofman A, Grobbee DE. Increased common carotid intima-media thickness: adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke 1997;28: 2442-7. Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994;236: 567-73. Salonen R, Salonen JT. Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Atherosclerosis 1990;81:33-40. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-9. Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995;75:455-9. de Groot E, Jukema JW, Montauban van Swijndregt AD, et al. Bmode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998;31:1561-7. O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22. Sorensen KE, Kristensen IB, Celermajer DS. Atherosclerosis in the human brachial artery. J Am Coll Cardiol 1997;29:318-22. Bots ML, Hofman A, Grobbee DE. Common carotid intima-media thickness and lower extremity arterial atherosclerosis: the Rotterdam Study. Arterioscler Thromb 1994;14:1885-91. Gnasso A, Irace C, Mattioli PL, et al. Carotid intima-media thickness and coronary heart disease risk factors. Atherosclerosis 1996;119: 7-15. Young W, Gofman JW, Tandy R, et al. The quantitation of atherosclerosis, III: the extent of correlation of degrees of atherosclerosis within and between the coronary and cerebral vascular beds. Am J Cardiol 1960;6:300-8. Adams MR, Nakagomi A, Keech A, et al. Carotid intima-media American Heart Journal Volume 141, Number 5 61. 62. 63. 64. thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation 1995;92:2127-34. Nagai Y, Metter EJ, Earley CJ, et al. Increased carotid artery intimal-medial thickness in asymptomatic older subjects with exerciseinduced myocardial ischemia. Circulation 1998;98:1504-9. Stensland-Bugge E, Bonaa KH, Joakimsen O. Reproducibility of ultrasonographically determined intima-media thickness is dependent on arterial wall thickness: the Tromso Study. Stroke 1997;28:1972-80. Espeland MA, Craven TE, Riley WA, et al. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses: Asymptomatic Carotid Artery Progression Study Research Group. Stroke 1996;27:480-5. Kanters SD, Elgersma OE, Banga JD, et al. Reproducibility of mea- Fathi and Marwick 703 surements of intima-media thickness and distensibility in the common carotid artery. Eur J Vasc Endovasc Surg 1998;16:28-35. 65. Dwyer JH, Sun P, Kwong-Fu H, et al. Automated intima-media thickness: the Los Angeles Atherosclerosis Study. Ultrasound Med Biol 1998;24:981-7. 66. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-7. 67. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
© Copyright 2019